[Rinsho ketsueki] The Japanese journal of clinical hematology · 2018
[Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Okano Motohiko, Matsumoto Takeshi, Nakamori Yoshiki, Ino Kazuko, Miyazaki Kana, Fujieda Atsushi, Sugimoto Yuka, Tawara Isao, Yamaguchi Motoko, Ohishi Kohshi, Miwa Hiroshi, Masuya Masahiro, Wada Hideo, Katayama Naoyuki
Аннотация
A 23-year-old man from Mie Prefecture, Japan, with past and family history of hematuria was diagnosed with influenza A and admitted to our hospital on the following day because of hemoglobinuria. He was diagnosed with thrombotic microangiopathy and was suspected of having atypical hemolytic uremic syndrome (aHUS). C3 p.I1157T missense mutation, which we had previously reported in eight aHUS patients from six families in Mie Prefecture, was identified. The laboratory findings and symptoms of our patient promptly improved after administering eculizumab. Little information is available on abnormalities of the complement system in aHUS or on mutation-specific outcomes of eculizumab therapy. Eculizumab was effective for treating our aHUS patient with C3 p.I1157T missense mutation.